Notably, IDH-mutant astrocytomas exhibiting both MGMTp methylation and elevated PRMT5 expression show significantly prolonged PFS with TMZ monotherapy compared to other subgroups (42). This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).